Non-specific immunologic CROSS-REACTIVITY can occur in patients with renal failure, pregnant women and neonates.
Note: In patients receiving Digibind therapy for treatment of digoxin overdose, the measured levels of digoxin are unreliable and may accurately reflect neither the total level of digoxin (bound and free) nor the level of free digoxin.
Although offered Stat, therapeutic decisions are typically not altered by stat results except in cases of accidental massive overdose when Digibind therapy is contemplated. Due to the long T1/2 for Digoxin it is generally acceptable to merely hold the next dose and obtain a routine Digoxin level.
See the lab manual's "A Guide on Drug Level Monitoring" (in the Chemistry Guide) for additional information.
Synonyms
Lanoxin
Sample Type
Serum or plasma
Collect
Gold top or Light Green top
Amount to Collect
1 mL blood
Preferred Volume
0.5 mL serum or plasma
Minimum Volume
0.3 mL serum or plasma
Remarks
Time to steady state: 3-5 days
Collect samples 30 minutes before next dose or at least 6-8 hours post dose.
Test Code
DIG
Performing Lab
Parnassus & Mission Bay Chemistry
Specimen Preparation
Refrigerate serum.
Preferred Volume
0.5 mL serum or plasma
Minimum Volume
0.3 mL serum or plasma
Units
µg/L
Reference Interval
Therapeutic: 0.5-2.0 µg/L
Critical Values
> 2.0 ug/L
Additional Information
Non-specific immunologic CROSS-REACTIVITY can occur in patients with renal failure, pregnant women and neonates.
Note: In patients receiving Digibind therapy for treatment of digoxin overdose, the measured levels of digoxin are unreliable and may accurately reflect neither the total level of digoxin (bound and free) nor the level of free digoxin.
Although offered Stat, therapeutic decisions are typically not altered by stat results except in cases of accidental massive overdose when Digibind therapy is contemplated. Due to the long T1/2 for Digoxin it is generally acceptable to merely hold the next dose and obtain a routine Digoxin level.
See the lab manual's "A Guide on Drug Level Monitoring" (in the Chemistry Guide) for additional information.
Collect samples 30 minutes before next dose or at least 6-8 hours post dose.
Collect
Gold top or Light Green top
Amount to Collect
1 mL blood
Sample Type
Serum or plasma
Preferred Volume
0.5 mL serum or plasma
Minimum Volume
0.3 mL serum or plasma
Specimen Preparation
Refrigerate serum.
Units
µg/L
Reference Interval
Therapeutic: 0.5-2.0 µg/L
Critical Values
> 2.0 ug/L
Synonyms
Lanoxin
Reported
STAT 1 hour, Routine 4 hours
Additional Information
Non-specific immunologic CROSS-REACTIVITY can occur in patients with renal failure, pregnant women and neonates.
Note: In patients receiving Digibind therapy for treatment of digoxin overdose, the measured levels of digoxin are unreliable and may accurately reflect neither the total level of digoxin (bound and free) nor the level of free digoxin.
Although offered Stat, therapeutic decisions are typically not altered by stat results except in cases of accidental massive overdose when Digibind therapy is contemplated. Due to the long T1/2 for Digoxin it is generally acceptable to merely hold the next dose and obtain a routine Digoxin level.
See the lab manual's "A Guide on Drug Level Monitoring" (in the Chemistry Guide) for additional information.
Non-specific immunologic CROSS-REACTIVITY can occur in patients with renal failure, pregnant women and neonates.
Note: In patients receiving Digibind therapy for treatment of digoxin overdose, the measured levels of digoxin are unreliable and may accurately reflect neither the total level of digoxin (bound and free) nor the level of free digoxin.
Although offered Stat, therapeutic decisions are typically not altered by stat results except in cases of accidental massive overdose when Digibind therapy is contemplated. Due to the long T1/2 for Digoxin it is generally acceptable to merely hold the next dose and obtain a routine Digoxin level.
See the lab manual's "A Guide on Drug Level Monitoring" (in the Chemistry Guide) for additional information.
Synonyms
Lanoxin
Collection
Sample Type
Serum or plasma
Collect
Gold top or Light Green top
Amount to Collect
1 mL blood
Preferred Volume
0.5 mL serum or plasma
Minimum Volume
0.3 mL serum or plasma
Remarks
Time to steady state: 3-5 days
Collect samples 30 minutes before next dose or at least 6-8 hours post dose.
Processing
Test Code
DIG
Performing Lab
Parnassus & Mission Bay Chemistry
Specimen Preparation
Refrigerate serum.
Preferred Volume
0.5 mL serum or plasma
Minimum Volume
0.3 mL serum or plasma
Result Interpretation
Units
µg/L
Reference Interval
Therapeutic: 0.5-2.0 µg/L
Critical Values
> 2.0 ug/L
Additional Information
Non-specific immunologic CROSS-REACTIVITY can occur in patients with renal failure, pregnant women and neonates.
Note: In patients receiving Digibind therapy for treatment of digoxin overdose, the measured levels of digoxin are unreliable and may accurately reflect neither the total level of digoxin (bound and free) nor the level of free digoxin.
Although offered Stat, therapeutic decisions are typically not altered by stat results except in cases of accidental massive overdose when Digibind therapy is contemplated. Due to the long T1/2 for Digoxin it is generally acceptable to merely hold the next dose and obtain a routine Digoxin level.
See the lab manual's "A Guide on Drug Level Monitoring" (in the Chemistry Guide) for additional information.
Collect samples 30 minutes before next dose or at least 6-8 hours post dose.
Collect
Gold top or Light Green top
Amount to Collect
1 mL blood
Sample Type
Serum or plasma
Preferred Volume
0.5 mL serum or plasma
Minimum Volume
0.3 mL serum or plasma
Specimen Preparation
Refrigerate serum.
Units
µg/L
Reference Interval
Therapeutic: 0.5-2.0 µg/L
Critical Values
> 2.0 ug/L
Synonyms
Lanoxin
Reported
STAT 1 hour, Routine 4 hours
Additional Information
Non-specific immunologic CROSS-REACTIVITY can occur in patients with renal failure, pregnant women and neonates.
Note: In patients receiving Digibind therapy for treatment of digoxin overdose, the measured levels of digoxin are unreliable and may accurately reflect neither the total level of digoxin (bound and free) nor the level of free digoxin.
Although offered Stat, therapeutic decisions are typically not altered by stat results except in cases of accidental massive overdose when Digibind therapy is contemplated. Due to the long T1/2 for Digoxin it is generally acceptable to merely hold the next dose and obtain a routine Digoxin level.
See the lab manual's "A Guide on Drug Level Monitoring" (in the Chemistry Guide) for additional information.
